Pediatric Precision Laboratory Advanced Neuroblastoma Therapy is a research study for children with a serious cancer called neuroblastoma. The study aims to test new ways of treating this cancer using special medicine based on each child's unique needs. This trial is open to children under 21 who have a high-risk form of neuroblastoma. The study combines regular cancer treatments with a new medicine, DFMO, to see if it helps. The trial is in two parts: one part is closed, and the other is open to new patients. Participants may need to undergo various tests to ensure they can safely join the study, like heart and kidney function tests. The risks and benefits will be explained thoroughly before any child joins.

Key Points:

• Study Length: Enroll before 120 days after transplant and be within 28 days of finishing local radiation if given.
• Eligibility: Children under 21 with high-risk neuroblastoma; must meet specific health criteria.
• Commitment: Participants must agree to use effective birth control during and six months post-treatment.

Before joining, all participants or their guardians must give written consent, confirming their understanding and willingness to participate.